Saturday, June 4, 2022, Chicago, Illinois, 7:00 PM – 9:30 PM Central Time (8:00 PM – 10:30 PM Eastern Time)

Cases from the Community: Investigators Discuss Available Research Guiding the Care of Patients with Gastrointestinal Cancers

A CME Hybrid Symposium Held in Conjunction with the 2022 ASCO Annual Meeting

Location
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:30 PM — Educational Meeting

Meeting Room
Grand Ballroom (Level 2)


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Tanios Bekaii-Saab, MD
Professor, Mayo Clinic College of Medicine and Science
Program Leader, Gastrointestinal Cancer
Mayo Clinic Cancer Center
Consultant, Mayo Clinic in Arizona
Chair, ACCRU Research Consortium
Phoenix, Arizona

Kristen K Ciombor, MD, MSCI
Associate Professor of Medicine
Division of Hematology/Oncology
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee

Eileen M O’Reilly, MD
Winthrop Rockefeller Endowed Chair in Medical Oncology
Section Head, Hepatopancreaticobiliary and Neuroendocrine Cancers
Co-Director, Medical Initiatives
David M Rubenstein Center for Pancreatic Cancer Research
Attending Physician, Member
Memorial Sloan Kettering Cancer Center
Professor of Medicine, Weill Cornell Medical College
New York, New York


Philip A Philip, MD, PhD, FRCP
Professor of Oncology and Pharmacology
Leader, GI and Neuroendocrine Oncology
Henry Ford Cancer Institute
Wayne State University
Detroit, Michigan

John Strickler, MD
Associate Professor
Duke University
Durham, North Carolina

Eric Van Cutsem, MD, PhD
Professor of Medicine
Digestive Oncology
University Hospitals Leuven
Leuven, Belgium

Moderator
Neil Love, MD
Research To Practice
Miami, Florida


This activity is supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Natera Inc, Seagen Inc, and Taiho Oncology Inc.
Program Schedule — Central Time
6:30 PM – 7:00 PM — Registration and Dinner
7:00 PM – 9:30 PM — Educational Meeting

MODULE 1: Integration of Targeted Therapy and Immunotherapy into the Management of Metastatic Colorectal Cancer (mCRC) — Dr Ciombor

  • Appropriate integration of encorafenib/cetuximab for patients with mCRC with BRAF V600E mutations; available results with and ongoing evaluation of earlier use of BRAF-targeted therapy
  • Rational incorporation of pembrolizumab, nivolumab and nivolumab/ipilimumab into the treatment of microsatellite instability-high/mismatch repair-deficient mCRC
  • Available clinical research findings with immune checkpoint inhibitor-based strategies in microsatellite-stable mCRC
  • Current appreciation of predictors of response to immunotherapy in CRC; ongoing effort to validate the 27-gene expression test as a predictor of immunotherapy response in CRC and other gastrointestinal tumors
  • Frequency of HER2 overexpression in patients with mCRC; available data with novel HER2-targeted therapies (eg, trastuzumab deruxtecan [T-DXd], tucatinib)
  • Incidence of KRAS p.G12C mutations in mCRC; early results with and ongoing evaluation of KRAS G12C inhibitors (eg, sotorasib, adagrasib)

MODULE 2: Other Considerations in the Management of Localized and Advanced CRC — Dr Strickler

  • Mechanistic rationale for and available data with longitudinal circulating tumor DNA (ctDNA) monitoring for patients with localized CRC
  • Ongoing studies (eg, BESPOKE CRC) examining the clinical utility of ctDNA testing for monitoring recurrence and guiding treatment decisions
  • Available data linking tumor sidedness to outcomes with EGFR antibody-based regimens for patients with mCRC
  • Factors in the selection and sequencing of approved regimens for patients with mCRC whose disease has progressed on multiple lines of therapy; rational incorporation of regorafenib and TAS-102
  • Available data with TAS-102 in combination with other systemic agents and in earlier disease stages
  • Other promising novel agents and strategies for patients with mCRC

MODULE 3: Current and Future Treatment Paradigm for Gastroesophageal Cancers — Prof Van Cutsem

  • Published outcomes from the Phase III CheckMate 577 study of adjuvant nivolumab for patients with resected esophageal or gastroesophageal junction (GEJ) cancer; appropriate selection of candidates for this strategy
  • Published data sets (eg, CheckMate 649, CheckMate 648, KEYNOTE-590, ORIENT-15, ORIENT-16, JUPITER-06) supporting the efficacy and safety of first-line regimens combining anti-PD-1/PD-L1 antibodies with chemotherapy or other immunotherapies for advanced gastric, GEJ and esophageal cancers
  • Principal outcomes from the Phase III KEYNOTE-811 trial supporting the use of first-line pembrolizumab/trastuzumab/chemotherapy for metastatic HER2-positive gastric/GEJ adenocarcinoma
  • Published efficacy and safety data with T-DXd in Japanese (DESTINY-Gastric01 trial) and Western (DESTINY-Gastric02 trial) patients; sequencing of T-DXd for patients with progressive HER2-positive disease
  • Optimal placement of ramucirumab and TAS-102 in current clinical algorithms; available data with novel ramucirumab- and TAS-102-containing combination regimens
  • Mechanism of action of zolbetuximab; available findings with first-line zolbetuximab/chemotherapy in patients with advanced claudin 18.2-positive gastric/GEJ adenocarcinoma
  • Other promising agents and strategies under investigation for gastroesophageal cancers

MODULE 4: Selection and Sequencing of Therapy for Advanced Hepatocellular Carcinoma (HCC) — Dr Philip

  • Current clinical roles of sorafenib and lenvatinib as first-line therapy for unresectable HCC; patient selection for tyrosine kinase inhibitor monotherapy
  • Long-term efficacy and safety findings supporting the use of first-line atezolizumab/bevacizumab for unresectable HCC; optimal integration into practice
  • Results from the Phase III HIMALAYA study demonstrating an overall survival advantage with a single priming dose of tremelimumab added to durvalumab compared to sorafenib alone for previously untreated advanced HCC; clinical implications
  • Available data with and ongoing evaluation of other novel combination strategies for HCC
  • Long-term outcomes with approved anti-angiogenic agents (eg, regorafenib, cabozantinib, ramucirumab) for patients with progressive HCC
  • Published efficacy and safety data with and current clinical roles of single-agent immune checkpoint inhibitors and nivolumab/ipilimumab for relapsed/refractory disease
  • Early data with neoadjuvant or adjuvant immunotherapy-based treatment for HCC and ongoing Phase III studies (eg, Checkmate 9DX, EMERALD-2, IMbrave050, KEYNOTE-937)

MODULE 5: Novel Treatment Strategies for Advanced Biliary Tract Cancers — Dr Bekaii-Saab

  • Findings from the Phase III TOPAZ-1 trial evaluating durvalumab in combination with chemotherapy as first-line treatment for advanced biliary tract cancers; implications for clinical practice
  • Spectrum of molecular alterations in cholangiocarcinoma and other biliary tract cancers; utility of genomic analyses to identify actionable molecular abnormalities
  • Clinical trial findings supporting the FDA accelerated approvals of pemigatinib and infigratinib for previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement
  • Efficacy and safety outcomes observed with other FGFR inhibitors (eg, futibatinib) in patients with cholangiocarcinoma harboring FGFR2 fusions or rearrangements
  • Ongoing Phase III evaluations of FGFR inhibition for treatment-naïve cholangiocarcinoma (eg, FIGHT-302, PROOF, FOENIX-CCA3)
  • Available efficacy and safety outcomes from the Phase III ClarIDHy study leading to the recent FDA approval of ivosidenib for cholangiocarcinoma with an IDH1 mutation; optimal integration into routine practice
  • Ongoing research evaluating ivosidenib in combination with chemotherapy for newly diagnosed cholangiocarcinoma
  • Early-phase data with HER2-targeted strategies (eg, T-DXd, zanidatamab) in HER2-positive biliary tract cancers
  • Other promising novel agents and strategies for patients with advanced biliary tract cancers

MODULE 6: Contemporary Management of Pancreatic Cancer — Dr O’Reilly

  • Clinical trials evaluating contemporary cytotoxic regimens with or without radiation therapy as preoperative therapy for resectable or borderline-resectable pancreatic adenocarcinoma (PAD)
  • Selection of adjuvant systemic therapy for patients with resected PAD
  • Optimal selection of first- and later-line treatment for patients with metastatic PAD; importance of age, comorbidities and prior therapy
  • Incidence of BRCA1/2 mutations and other DNA damage repair deficiencies in patients with PAD; guideline-endorsed algorithms for genetic testing
  • Long-term efficacy and safety findings with and optimal integration of olaparib as maintenance therapy after first-line chemotherapy for patients with metastatic PAD and a germline BRCA mutation
  • Available data with PARP inhibitors in combination with other anticancer therapies and/or in earlier disease stages
  • Other novel agents and strategies under investigation for localized and advanced pancreatic cancer

Target Audience
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of gastrointestinal cancers.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Develop a long-term care plan for patients diagnosed with metastatic colorectal cancer, considering biomarker profile, tumor location, prior exposure to systemic therapy, symptomatology, performance status (PS) and personal goals of treatment.
  • Use HER2 status, PD-L1 combined positive score and other clinical and biologic factors to optimize the selection and sequencing of systemic therapy for patients with locally advanced or metastatic gastric, gastroesophageal junction and esophageal cancers.
  • Consider age, PS, degree of liver function and other clinical factors in the selection of first- and later-line therapy for patients with unresectable or metastatic hepatocellular carcinoma.
  • Recall clinical trial data with approved and investigational systemic interventions for localized, locally advanced and metastatic pancreatic adenocarcinoma, and establish an evidence-based approach to therapeutic selection for patients.
  • Appreciate the molecular heterogeneity of cholangiocarcinomas, and apply available clinical research findings to individualize therapy for patients with unresectable and metastatic disease.
  • Appraise available and emerging data with investigational agents currently in clinical testing for gastrointestinal cancers, and where applicable, refer eligible patients for clinical trial participation.

CME Credit Form
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTYDr Philip has no relevant conflicts of interest to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Dr Bekaii-SaabConsulting Agreements (to Institution): Arcus Biosciences, Bayer HealthCare Pharmaceuticals, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Merck, Pfizer Inc, Seagen Inc; Consulting Agreements (to Self): AbbVie Inc, Aptitude Health, AstraZeneca Pharmaceuticals LP, BeiGene Ltd, Boehringer Ingelheim Pharmaceuticals Inc, Celularity, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, Exact Sciences, Foundation Medicine, Illumina, Janssen Biotech Inc, Kanaph Therapeutics, MJH Life Sciences, Natera Inc, Swedish Orphan Biovitrum AB, Stemline Therapeutics Inc, Treos Bio; Data and Safety Monitoring Board/Committee: 1Globe Health Institute, AstraZeneca Pharmaceuticals LP, Eisai Inc, Exelixis Inc, FibroGen Inc, Merck, Pancreatic Cancer Action Network, Suzhou Kintor; Inventions/Patents: WO/2018/183488 licensed to Imugene, WO/2019/055687 licensed to Recursion; Research Funding (to Institution): AbGenomics, Agios Pharmaceuticals Inc, Arcus Biosciences, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Atreca, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merus BV, Mirati Therapeutics, Novartis, Pfizer Inc, Seagen Inc, Sumitomo Dainippon Pharma Oncology Inc; Scientific Advisory Board: Immuneering Corporation, Imugene, Replimune, Sun Biopharma, Xilis. Dr CiomborAdvisory Committee: Array BioPharma Inc, a subsidiary of Pfizer Inc, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Personalis Inc, Pfizer Inc, Replimune; Consulting Agreements: Merck, Pfizer Inc, Seagen Inc; Contracted Research: Bristol-Myers Squibb Company, Calithera Biosciences, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, NuCana, Pfizer Inc. Dr O’ReillyConsulting Agreements: Agios Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, AstraZeneca Pharmaceuticals LP, Autem Medical, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Berry Genomics, Celgene Corporation, Cend Therapeutics Inc, CytomX Therapeutics, Eisai Inc, Exelixis Inc, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Helio Health, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, MiNA Therapeutics, QED Therapeutics, Rafael Pharmaceuticals Inc, RedHill Biopharma Ltd, Silenseed Ltd, SillaJen, Sobi, Surface Oncology, TheraBionic, twoXAR Inc, Vector Pharma, Yiviva; Contracted Research: Agios Pharmaceuticals Inc, Arcus Biosciences, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BioNTech, Bristol-Myers Squibb Company, Celgene Corporation, Flatiron Health, Genentech, a member of the Roche Group, Genoscience Pharma, Incyte Corporation, Polaris Pharmaceuticals, Puma Biotechnology Inc, QED Therapeutics, SillaJen, Yiviva. Dr StricklerAdvisory Committee: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Inivata, Natera Inc, Pfizer Inc, Seagen Inc, Silverback Therapeutics, Viatris; Consulting Agreement: Mereo BioPharma; Contracted Research: AbbVie Inc, Amgen Inc, AStar D3, Bayer HealthCare Pharmaceuticals, Curegenix, Daiichi Sankyo Inc, Erasca, Genentech, a member of the Roche Group, Gossamer Bio, Nektar, Sanofi Genzyme, Seagen Inc, Silverback Therapeutics; Data and Safety Monitoring Board/Committee: AbbVie Inc, Pionyr Immunotherapeutics. Prof Van CutsemAdvisory Committee: AbbVie Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, Biocartis, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, GlaxoSmithKline, Halozyme Inc, Helsinn Healthcare SA, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Mirati Therapeutics, Novartis, Pierre Fabre, Roche Laboratories Inc, Seagen Inc, Servier Pharmaceuticals LLC, Sirtex Medical Ltd, Taiho Oncology Inc, Terumo Medical Corporation, TRIGR (trial), Zymeworks Inc; Research Grants to Institution: Amgen Inc, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Ipsen Biopharmaceuticals Inc, Lilly, Merck KGaA, Merck Sharp & Dohme Corp, Novartis, Roche Laboratories Inc, Servier Pharmaceuticals LLC.

MODERATORDr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab, Gilead Sciences Inc, GlaxoSmithKline, Grail Inc, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Mersana Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seagen Inc, Servier Pharmaceuticals LLC, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc and Zymeworks Inc.

Research To Practice CME Planning Committee Members, Staff and Reviewers — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Lilly, Natera Inc, Seagen Inc, and Taiho Oncology Inc.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of gastrointestinal cancers.

There is no fee to participate in this program or live webcast of this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.

Registration for in-person meeting

In order to attend this in-person event, please register here.

Registration for event »
 
Registration for live webcast

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

Registration for Webcast »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.

 

Not an official event of the 2022 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO®, CancerLinQ®, or Conquer Cancer®, the ASCO Foundation.